Safety issues associated with the use of angiotensin-converting enzyme inhibitors

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.5, Iss.6, 2006-11, pp. : 739-740

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ongoing trials involving angiotensin-converting enzyme inhibitors

By Nadar Sunil Lip Gregory YH

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1633-1643

Informa Healthcare

Access to resources Recommend Favorite

Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors

Current Pharmaceutical Design, Vol. 21, Iss. 13, 2015-04 ,pp. : 1764-1775

Bentham Science Publishers

Access to resources Recommend Favorite

Acute adverse reactions associated with angiotensin-converting enzyme inhibitors: genetic factors and therapeutic implications

By Nikpoor Borzoo Duan Qing Ling Rouleau Guy A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 11, 2005-09 ,pp. : 1851-1856

Informa Healthcare

Access to resources Recommend Favorite

Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium

By Lenz O. Schmid B. Kilter H. La Rosee K. Flesch M. Kuhn-Regnier F. Sudkamp M. Bohm M.

European Journal of Pharmacology, Vol. 294, Iss. 1, 1995-01 ,pp. : 17-27

Elsevier

Access to resources Recommend Favorite

Angiotensin-converting enzyme inhibitors can potentiate ozone-induced airway hyperresponsiveness

By Matsubara S. Kikkawa H. Kaminuma O. Ikezawa K.

European Journal of Pharmacology, Vol. 337, Iss. 2, 1997-10 ,pp. : 259-265

Elsevier

Access to resources Recommend Favorite